Vaccine Weekly
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Vaccine Weekly
We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.
Human Papillomavirus Vaccines
Research from University of Cambridge, Department of Pathology provides new data on human papillomavirus vaccines
November 5th, 2008
A report, 'Immunobiology of human papillomavirus infection and vaccination - implications for second generation vaccines,' is newly published data in Vaccine. "Prophylactic human papillomavirus (HPV) L1 virus like particle (VLP) vaccines have been shown, in large clinical trials, to be very immunogenic, well-tolerated and highly efficacious against genital disease caused by the vaccine HPV types. However these vaccines, at the present, protect against only two of the 15 oncogenic genital HPV types, they are expensive, delivered by intramuscular injection and require a cold chain," scientists in Cambridge, the United Kingdom report. "The challenges are to develop...
Source: Vaccine Weekly (2008-11-05)
|
